Omeprazol Farma Tarbis (Omeprazole)

Omeprazole acts on the gastric acid secretion pathway and is indicated for several acid‑related disorders.

• Gastro‑esophageal reflux disease (GERD): provides symptomatic relief and promotes healing of esophageal erosion.
• Peptic ulcer disease: supports ulcer healing and reduces risk of recurrence.
• Zollinger‑Ellison syndrome: controls excessive gastric acid production associated with the condition.
• Helicobacter pylori eradication regimens: used as part of combination therapy to improve eradication rates.
• NSAID‑induced ulcer prophylaxis: lowers the risk of ulcer development in patients requiring long‑term NSAID therapy.

• Omeprazole selectively and irreversibly inhibits the H+/K+‑ATPase enzyme (the gastric proton pump) located on the secretory surface of parietal cells. By blocking this final step of acid secretion, it markedly reduces both basal and stimulated gastric acidity, allowing mucosal healing and symptom control in acid‑related disorders.

Adverse reactions to omeprazole are generally mild to moderate and vary with duration of therapy.

Common Side Effects

• Headache: mild, transient headache reported by some patients.
• Diarrhea: loose stools occurring during early treatment.
• Nausea: occasional feeling of queasiness.
• Abdominal pain: mild discomfort in the stomach area.
• Flatulence: increased intestinal gas.
• Constipation: reduced bowel movements.

Serious or Rare Side Effects

• Clostridioides difficile infection: severe colitis associated with prolonged use.
• Hypomagnesemia: low serum magnesium levels with long‑term therapy.
• Vitamin B12 deficiency: impaired absorption with extended treatment.
• Acute interstitial nephritis: kidney inflammation reported rarely.
• Stevens‑Johnson syndrome: severe skin reaction, extremely rare.
• Hepatic injury: abnormal liver function tests in rare cases.

When prescribing omeprazole, clinicians should consider several safety aspects.

• Assess need for long‑term therapy: evaluate risk‑benefit before chronic use.
• Monitor electrolytes: check magnesium and calcium levels during extended treatment.
• Review concomitant medications: consider potential drug‑drug interactions.
• Use with caution in hepatic impairment: dose adjustment may be required.
• Pregnancy and lactation: weigh benefits against potential risks.
• Store at ambient temperature: keep below 25°C, protect from moisture and light.

Omeprazole can affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid)

• Clopidogrel: reduced antiplatelet effect, may increase cardiovascular risk.
• Atazanavir: decreased absorption, loss of antiviral efficacy.
• Dasatinib: lowered plasma concentrations, reduced therapeutic effect.

Moderate Interactions (Monitor Closely)

• Warfarin: potential increase in INR, monitor coagulation parameters.
• Phenytoin: altered serum levels, adjust dose as needed.
• Methotrexate: increased exposure, especially at high doses.
• Digoxin: modest rise in serum concentration, observe for toxicity.